SecBot SecBot
144 ·Filed Nov 12, 2026

BLCO

Bausch & Lomb Corp
NEUTRAL
Impact 2/10
Horizonimmediate Processed4d 11h ago SEC0001959173-26-007964
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

This is a small, routine sale by a former director. No material impact expected. Monitor for any additional insider selling patterns in future filings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$21.14
T+0 close · Nov 12, 2026 · via day close
Latest settled
−0.24%
T+1 · $21.09
Vs SPY
+0.13%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $21.14entry
  2. T+1 · 4d ago −0.24%α +0.13% · $21.09
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Former director Karen Ling filed a Form 144 notice to sell 12,838 common shares of Bausch & Lomb Corp, valued at approximately $269,746. The shares were acquired through restricted stock vesting on May 20, 2025, and the sale is planned for November 12, 2026. This is a routine insider sale by a former director, representing a small fraction of the company's $7.6B market cap.

Key Facts

  • Former director Karen Ling intends to sell 12,838 shares of BLCO common stock.
  • Estimated aggregate value of the proposed sale is $269,746.08.
  • Shares were acquired via restricted stock vesting on May 20, 2025, as compensation.
  • The sale is planned for execution on November 12, 2026.
  • The filing is an advance notice of intent to sell, not a completed transaction.

Financial Impact

Approximately $270K, representing about 0.0035% of BLCO's $7.6B market cap.

dilution

Risk Factors

  • Form 144 is only an intent to sell; the sale may not occur.
  • No other insider sales or context provided to suggest a broader trend.

Market Snapshot

Exchange
NYSE
Sector
Ophthalmic Goods
Analyst Consensus
58% bullish (19 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-007964
Document: 0001959173-26-007964-index.html0001959173-26-007964
Document: 0001959173-26-007964.txt0001959173-26-007964

Track record

24 reports on BLCO

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +16.89% at T+20 after the Oct 1, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $21.14 Now $20.88 −1.23% settles Nov 19
  2. Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.03 to $21.37 Now $20.88 +4.24% ▲ +6.69% +7.28% vs SPY
  3. Oct 29, 202618d ago 144 Neutral 3/10 Entry $20.00 to $19.99 Now $20.88 +4.40% ▼ −0.05% +2.65% vs SPY
  4. Oct 28, 202619d ago 8-K Neutral 2/10 Entry $20.40 to $19.92 Now $20.88 +2.35% ▼ −2.35% +2.37% vs SPY
  5. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $20.40 to $20.60 Now $20.88 +2.35% ▲ +0.98% +1.69% vs SPY
  6. Oct 13, 20264w ago 8-K Mixed 6/10 Entry $15.81 to $16.93 Now $20.88 +32.07% ▲ +7.08% +8.24% vs SPY
  7. Oct 1, 20266w ago Court Ruling Bullish 4/10 Entry $17.11 to $17.30 Now $20.88 +22.03% ▲ +1.11% −0.05% vs SPY
  8. Sep 28, 20267w ago 144 Neutral 2/10 Entry $16.95 to $17.17 Now $20.88 +23.19% ▲ +1.30% +0.09% vs SPY
  9. Aug 14, 202613w ago 3 / CLUSTER Neutral 2/10 Entry $17.00 to $17.32 Now $20.88 +22.82% ▲ +1.88% +3.07% vs SPY
  10. Aug 14, 202613w ago 3 Neutral 2/10 Entry $17.00 to $17.32 Now $20.88 +22.82% ▲ +1.88% +3.07% vs SPY
Showing 10 of 24

US Market Status

Market Closed · Opens Wed (10h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026